Levilimab (anti-IL-6Ra) - Primary antibody, specific to IL6R, >95% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of Interleukin-6 receptor alpha subunit inhibitor
Levilimab (anti-IL-6Ra) - Primary antibody, specific to IL6R, >95% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of Interleukin-6 receptor alpha subunit inhibitor
INHIBITOR of Interleukin-6 receptor alpha subunit inhibitor
Product Description
Levilimab (anti-IL-6Ra) is a fully human anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab (anti-IL-6Ra) is an inflammation-alleviating antibody. Levilimab (anti-IL-6Ra) can be used for the research of rheumatoid.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
28.0 kDa (Light Chain) & 55.0 kDa (Heavy Chain), under reducing conditions; 217.8 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Purity
>95% (SDS-PAGE&SEC)
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2035008-70-7
Images
Levilimab (anti-IL-6Ra) (Ab182913) - ELISA Immobilized Recombinant Human IL-6Ra protein (rp181252) at 1.0 μg/mL can bind Levilimab (anti-IL-6Ra) (Ab182913) with the EC50 of 78.97 ng/mL.
Levilimab (anti-IL-6Ra) (Ab182913) - SEC The purity of Levilimab (anti-IL-6Ra) (Ab182913) is more than 95% verified by HPLC.